Combined Multiomics and In Silico Approach Uncovers PRKAR1A as a Putative Therapeutic Target in Multi-Organ Dysfunction Syndrome

Despite all epidemiological, clinical, and experimental research efforts, therapeutic concepts in sepsis and sepsis-induced multi-organ dysfunction syndrome (MODS) remain limited and unsatisfactory. Currently, gene expression data sets are widely utilized to discover new biomarkers and therapeutic targets in diseases. In the present study, we analyzed MODS expression profiles (comprising 13 sepsis and 8 control samples) retrieved from NCBI-GEO and found 359 differentially expressed genes (DEGs), among which 170 were downregulated and 189 were upregulated. Next, we employed the weighted gene co-expression network analysis (WGCNA) to establish a MODS-associated gene co-expression network (weighted) and identified representative module genes having an elevated correlation with age. Based on the results, a turquoise module was picked as our hub module. Further, we constructed the PPI network comprising 35 hub module DEGs. The DEGs involved in the highest-confidence PPI network were utilized for collecting pathway and gene ontology (GO) terms using various libraries. Nucleotide di- and triphosphate biosynthesis and interconversion was the most significant pathway. Also, 3 DEGs within our PPI network were involved in the top 5 significantly enriched ontology terms, with hypercortisolism being the most significant term. PRKAR1A was the overlapping gene between top 5 significant pathways and GO terms, respectively. PRKAR1A was considered as a therapeutic target in MODS, and 2992 ligands were screened for binding with PRKAR1A. Among these ligands, 3 molecules based on CDOCKER score (molecular dynamics simulated-based score, which allows us to rank the binding poses according to their quality and to identify the best pose for each system) and crucial interaction with human PRKAR1A coding protein and protein kinase-cyclic nucleotide binding domains (PKA RI alpha CNB-B domain) via active site binding residues, viz. Val283, Val302, Gln304, Val315, Ile327, Ala336, Ala337, Val339, Tyr373, and Asn374, were considered as lead molecules.

[1]  L. Qin,et al.  Selected by bioinformatics and molecular docking analysis, Dhea and 2–14,15-Eg are effective against cholangiocarcinoma , 2022, PloS one.

[2]  Cheng Zhu,et al.  An integrative network-based approach for drug target indication expansion , 2021, PloS one.

[3]  A. Nierhaus,et al.  Sepsis—Pathophysiology and Therapeutic Concepts , 2021, Frontiers in Medicine.

[4]  W. Wang,et al.  Long Noncoding RNA: Regulatory Mechanisms and Therapeutic Potential in Sepsis , 2021, Frontiers in Cellular and Infection Microbiology.

[5]  Barbara Zdrazil,et al.  Moving targets in drug discovery , 2020, Scientific Reports.

[6]  Xiaomin Shen,et al.  Accuracy of circulating microRNAs in diagnosis of sepsis: a systematic review and meta-analysis , 2020, Journal of Intensive Care.

[7]  G. Sygitowicz,et al.  Molecular mechanisms of organ damage in sepsis: an overview , 2020, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[8]  Manar G Gebriel,et al.  Evaluation of Procalcitonin, C-Reactive Protein, and Interleukin-6 as Early Markers for Diagnosis of Neonatal Sepsis , 2020, International journal of microbiology.

[9]  S. Meng,et al.  Diagnostic value of serum soluble triggering expressed receptor on myeloid cells 1 (sTREM-1) in suspected sepsis: a meta-analysis , 2020, BMC Immunology.

[10]  Jisoo Lee,et al.  Metabolomics and the Microbiome as Biomarkers in Sepsis. , 2020, Critical care clinics.

[11]  Jussi Paananen,et al.  An omics perspective on drug target discovery platforms , 2019, Briefings Bioinform..

[12]  J. John,et al.  Differential discounting in the economic evaluation of healthcare programs , 2019, Cost Effectiveness and Resource Allocation.

[13]  Muming Yu,et al.  Pathological alteration and therapeutic implications of sepsis-induced immune cell apoptosis , 2019, Cell Death & Disease.

[14]  C. Pierrakos,et al.  The use of soluble urokinase plasminogen activator receptor (suPAR) as a marker of sepsis in the emergency department setting. A current review , 2019, Acta clinica Belgica.

[15]  H. Puthalakath,et al.  Sepsis: Inflammation Is a Necessary Evil , 2019, Front. Cell Dev. Biol..

[16]  J. Timsit,et al.  Septic shock among patients with systemic lupus erythematosus: Short and long-term outcome. Analysis of a French nationwide database. , 2019, The Journal of infection.

[17]  Wenping Zhang,et al.  Circulating microRNAs as biomarkers for Sepsis secondary to pneumonia diagnosed via Sepsis 3.0 , 2019, BMC Pulmonary Medicine.

[18]  M. Pinsky,et al.  Cardiovascular determinants of resuscitation from sepsis and septic shock , 2019, Critical Care.

[19]  M. Hayakawa,et al.  Epidemiology of disseminated intravascular coagulation in sepsis and validation of scoring systems , 2019, Journal of critical care.

[20]  Albert-László Barabási,et al.  Network-based prediction of drug combinations , 2019, Nature Communications.

[21]  Pilhan Kim,et al.  Neutrophils disturb pulmonary microcirculation in sepsis-induced acute lung injury , 2019, European Respiratory Journal.

[22]  J. Koyner,et al.  Sepsis associated acute kidney injury , 2019, British Medical Journal.

[23]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[24]  R. Bellomo,et al.  Sepsis‐induced acute kidney injury: A disease of the microcirculation , 2018, Microcirculation.

[25]  Geetanjali Dang,et al.  Severe sepsis and cardiac arrhythmias. , 2018, Annals of translational medicine.

[26]  L. Moldawer,et al.  Chronic Critical Illness and the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome , 2018, Front. Immunol..

[27]  Daniel Brodie,et al.  Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment , 2018, JAMA.

[28]  Anna-Maria Burgdorff,et al.  Vasoplegia in patients with sepsis and septic shock: pathways and mechanisms , 2018, The Journal of international medical research.

[29]  C. Sergi,et al.  Cardiovascular dysfunction in sepsis at the dawn of emerging mediators. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[30]  Song-Tao Shou,et al.  Sepsis-Induced Cardiomyopathy: Mechanisms and Treatments , 2017, Front. Immunol..

[31]  Henry E. Wang,et al.  Risk of Acute Coronary Heart Disease After Sepsis Hospitalization in the REasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  Xuhua Xia,et al.  Bioinformatics and Drug Discovery , 2017, Current topics in medicinal chemistry.

[33]  Matthew J. Maiden,et al.  Acute kidney injury in sepsis , 2017, Intensive Care Medicine.

[34]  N. Kissoon,et al.  Current challenges in the management of sepsis in ICUs in resource-poor settings and suggestions for the future , 2017, Intensive Care Medicine.

[35]  Alan E. Jones,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 , 2017, Intensive Care Medicine.

[36]  C. Evans,et al.  Impact of thrombosis on pulmonary endothelial injury and repair following sepsis. , 2017, American journal of physiology. Lung cellular and molecular physiology.

[37]  F. Tacke,et al.  Liver — guardian, modifier and target of sepsis , 2017, Nature Reviews Gastroenterology &Hepatology.

[38]  M. Passariello,et al.  Hemodynamic coherence in sepsis. , 2016, Best practice & research. Clinical anaesthesiology.

[39]  C. Ronco,et al.  Cardiorenal Syndrome Type 5 in Sepsis: Role of Endotoxin in Cell Death Pathways and Inflammation , 2016, Kidney and Blood Pressure Research.

[40]  M. Koçak,et al.  Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial , 2016, Critical Care.

[41]  J. Takala,et al.  Understanding circulatory failure in sepsis , 2016, Intensive Care Medicine.

[42]  R. Hotchkiss,et al.  Sepsis and septic shock , 2016, Nature Reviews Disease Primers.

[43]  Sreenivas Enaganti,et al.  Molecular docking and pharmacophore studies of heterocyclic compounds as Heat shock protein 90 (Hsp90) Inhibitors , 2016, Bioinformation.

[44]  D. Warren,et al.  Longitudinal Study of the Effects of Bacteremia and Sepsis on 5-year Risk of Cardiovascular Events. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  Andrew D. Rouillard,et al.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..

[46]  Sang-Bum Hong,et al.  Sepsis and Acute Respiratory Distress Syndrome: Recent Update , 2016, Tuberculosis and respiratory diseases.

[47]  R. Bellomo,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[48]  R. Veach,et al.  New paradigms in sepsis: from prevention to protection of failing microcirculation , 2015, Journal of thrombosis and haemostasis : JTH.

[49]  W. McGee,et al.  The Economic and Humanistic Burden of Severe Sepsis , 2015, PharmacoEconomics.

[50]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[51]  G. Van den Berghe,et al.  Cholestatic liver (dys)function during sepsis and other critical illnesses , 2015, Intensive Care Medicine.

[52]  Shulin Li,et al.  The Role of the Liver in Sepsis , 2014, International reviews of immunology.

[53]  Venu M. Velagapudi,et al.  Correlation of left ventricular systolic dysfunction determined by low ejection fraction and 30-day mortality in patients with severe sepsis and septic shock: a systematic review and meta-analysis. , 2014, Journal of critical care.

[54]  Q. Zou,et al.  Presepsin as a novel sepsis biomarker , 2014 .

[55]  R. Hotchkiss,et al.  Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy , 2013, Nature Reviews Immunology.

[56]  V. Pettilä,et al.  Acute kidney injury in patients with severe sepsis in Finnish Intensive Care Units , 2013, Acta anaesthesiologica Scandinavica.

[57]  Edward Y. Chen,et al.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.

[58]  N. Nesseler,et al.  The liver in sepsis , 2012 .

[59]  A. Khwaja KDIGO Clinical Practice Guidelines for Acute Kidney Injury , 2012, Nephron Clinical Practice.

[60]  Arthur S Slutsky,et al.  Acute Respiratory Distress Syndrome The Berlin Definition , 2012 .

[61]  P. Bruneval,et al.  Histopathology of septic shock induced acute kidney injury: apoptosis and leukocytic infiltration , 2010, Intensive Care Medicine.

[62]  Ravi Iyengar,et al.  Network analyses in systems pharmacology , 2009, Bioinform..

[63]  S. Bagshaw,et al.  Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy , 2009, Intensive Care Medicine.

[64]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[65]  Daniel Talmor,et al.  Occult hypoperfusion and mortality in patients with suspected infection , 2007, Intensive Care Medicine.

[66]  Jenine K. Harris,et al.  Network Analysis in Public Health: History, Methods, and Applications , 2022 .

[67]  A. Mebazaa,et al.  Septic shock: a heart story since the 1960s , 2006, Intensive Care Medicine.

[68]  C. Sprung,et al.  Sepsis in European intensive care units: Results of the SOAP study* , 2006, Critical care medicine.

[69]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[70]  G. Su,et al.  Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. , 2002, American journal of physiology. Gastrointestinal and liver physiology.

[71]  V. Pettilä,et al.  Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis , 2002, Intensive Care Medicine.